Literature DB >> 14526417

Inhibitory effect of recombinant endostatin on angiogenesis and tumor growth of hepatoma.

Peiyuan Li1, Zuohua Feng, Guimei Zhang, Hui Zhang, Shengli Xue, Bo Huang, Jusheng Lin.   

Abstract

To study the influence of recombinant endostatin on angiogenesis and tumor growth of mice H22 hepatoma, tumor models were constructed by injecting H22 hepatoma cells into the leg muscle of mice. Recombinant endostatin was produced by gene engineering in E. coli. The recombinant protein was injected subcutaneously to treat transplanted hepatoma faraway. The weight of tumors was measured, and the changes of necrosis of tumor cells and vessel density were observed by immunohistochemistry. The results suggested that the growth of hepatoma models transplanted in the muscle of legs was suppressed by recombinant endostatin. The density of vascularity was decreased, but the necrosis of tumor cells increased. The inhibitory effect of recombinant endostatin on angiogenesis and tumor growth of hepatoma was not affected after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14526417     DOI: 10.1007/bf02829497

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  8 in total

Review 1.  Treatment of hepatocellular carcinoma.

Authors:  J Bruix
Journal:  Hepatology       Date:  1997-02       Impact factor: 17.425

2.  Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.

Authors:  F Rastinejad; P J Polverini; N P Bouck
Journal:  Cell       Date:  1989-02-10       Impact factor: 41.582

3.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

4.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

Review 5.  [Treatment of liver cancer: current status and future prospectives].

Authors:  Y Kamohara; T Kanematsu
Journal:  Gan To Kagaku Ryoho       Date:  2000-07

6.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

7.  Angiostatin induces and sustains dormancy of human primary tumors in mice.

Authors:  M S O'Reilly; L Holmgren; C Chen; J Folkman
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

Review 8.  Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.

Authors:  N Weidner
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

  8 in total
  2 in total

1.  Splenectomy suppresses growth and metastasis of hepatocellular carcinoma through decreasing myeloid-derived suppressor cells in vivo.

Authors:  Xin Long; Jian Wang; Jian-Ping Zhao; Hui-Fang Liang; Peng Zhu; Qi Cheng; Qian Chen; Yan-Hui Wu; Zhan-Guo Zhang; Bi-Xiang Zhang; Xiao-Ping Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

2.  Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma.

Authors:  Pei-Yuan Li; Ju-Sheng Lin; Zuo-Hua Feng; Yu-Fei He; He-Jun Zhou; Xin Ma; Xiao-Kun Cai; De-An Tian
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.